Addition of tucatinib to trastuzumab/pertuzumab after local therapy for isolated intracranial progression in HER2-positive metastatic breast cancer: primary results of the phase II BRIDGET trial☆

ESMO Open · Elsevier

Аннотация

Publication date: December 2026 Source: ESMO Open, Volume 11, Issue 12 Author(s): S.L. Sammons, A.E.D. Van Swearingen, N.A. Bagegni, L.A. Huppert, S.-H. Jung, G. Broadwater, K. Strickland, S. Beyer, A. Conlin, A. Morikawa, R.K. Murthy, N.U. Lin, C.K. Anders, Allison Lipps, Maura Buckley, Ashley Hughes, Jamie Douthitt, Brian Kostoff, Lisa Wood, Stephanie Masheck

Читать у издателя →

Похожие статьи